KIMS Hospitals Financial Highlights and ESG Initiatives slide image

KIMS Hospitals Financial Highlights and ESG Initiatives

KIMS HOSPITALSTM Financial & Operational Highlights - 1/2 (Rupees in Millions) FINANCIAL HIGHLIGHTS Q3 FY 23 Consolidated • From 1st September 22, M/s SPANV Medisearch Lifesciences Private Limited (Kingsway Hospital, Nagpur) has become subsidiary of "KIMS Hospitals", post-acquisition of 51% stake. Therefore, Q3 FY23 includes 3 months performance whereas Q2 FY23 includes only 1 month performance of Nagpur unit. • Key financial figures Ex. Nagpur unit are provided for better QoQ comparison. [Adjusted EBITDA margin improved by 0.1% to 27.2% on QoQ basis] Consolidated Nagpur Consolidated Ex. Nagpur Particulars Q3 FY 23 Q2 FY 23 Q3 FY 22 QoQ YoY Q3 FY23 Q2 FY23 # Q3 FY 23 Q2 FY 23 QoQ YoY Total Income 5,686.1 5,732.8 3,959.6 372.5 143.2 5,313.7 5,589.6 Less Other Income 64.5 92.0 23.9 1.2 0.6 63.3 91.5 Revenue from Operations 5,621.6 5,640.7 3,935.7 -0.3% 42.8% 371.2 142.6 5,250.4 5,498.1 -4.5% 33.4% PBT 1,128.2 1,226.3 1,103.8 -8.0% 2.2% -80.7 -25.7 1,208.8 1,252.0 -3.5% 9.5% Add Interest 115.2 78.8 29.7 60.0 23.5 55.3 55.3 Add Depreciation 332.9 311.2 188.1 37.2 16.7 295.7 294.5 Reported EBITDA (Including other income) as per Financials 1,576.3 1,616.3 1,321.5 -2.5% 19.3% 16.5 14.5 1,559.8 1,601.8 -2.6% 18.0% Less Other Income 64.5 92.0 23.9 1.2 0.6 63.3 91.5 Less INDAS 116 67.9 77.3 8.2 67.9 77.3 EBITDA Pre INDAS & Other Income 1,444.0 1,447.0 1,289.4 -0.2% 12.0% 15.3 14.0 1,428.7 1,433.0 -0.3% 10.8% EBITDA % to Revenue from Operations Add: One off Old Luxury Tax Settlement 25.7% 25.7% 32.8% 4.1% 9.8% 27.2% 26.1% 54.9 54.9 Add: One off Expenses in Q3 (Nagpur) Adjusted EBITDA 26.1 26.1 1,470.1 1,501.9 1,289.4 -2.1% 14.0% 41.4 14.0 1,428.7 1,487.9 -4.0% 10.8% Adjusted EBITDA % 26.2% 26.6% 32.8% 11.1% 9.8% 27.2% 27.1% #Q2 FY23 represents 1 month (Sep '22) performance Private & Confidential 14
View entire presentation